5-HT2A Receptor Protein

Migration, Crosslink

📖

5-HT2A Receptor Protein

active

wiki page Created: 2026-04-02T07:19:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-5-ht2a-receptor

📖 Wiki Page

protein2339 wordssynced 2026-04-02

5-HT2A Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">5-HT2A Receptor Protein</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">5-HT2A Antagonists (nelotanserin)</td>
<td>Reduce LID</td>
</tr>
<tr>
<td class="label">5-HT2A Inverse Agonists</td>
<td>Stabilize inactive state</td>
</tr>
<tr>
<td class="label">Allosteric Modulators</td>
<td>Enhance therapeutic signaling</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Psilocybin</td>
<td>5-HT2A agonist</td>
</tr>
<tr>
<td class="label">LSD</td>
<td>5-HT2A/5-HT1A agonist</td>
</tr>
<tr>
<td class="label">DMT</td>
<td>5-HT2A agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Clozapine</td>
<td>5-HT2A/D2 antagonist</td>
</tr>
<tr>
<td class="label">Risperidone</td>
<td>5-HT2A/D2 antagonist</td>
</tr>
<tr>
<td class="label">Nelotanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">NCT ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04197379</td>
<td>Psilocybin</td>
</tr>
<tr>
<td class="label">NCT03712982</td>
<td>Nelotanserin</td>
</tr>
<tr>
<td class="label">NCT02963255</td>
<td>Risperidone</td>
</tr>
</table>

...

5-HT2A Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">5-HT2A Receptor Protein</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">5-HT2A Antagonists (nelotanserin)</td>
<td>Reduce LID</td>
</tr>
<tr>
<td class="label">5-HT2A Inverse Agonists</td>
<td>Stabilize inactive state</td>
</tr>
<tr>
<td class="label">Allosteric Modulators</td>
<td>Enhance therapeutic signaling</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Psilocybin</td>
<td>5-HT2A agonist</td>
</tr>
<tr>
<td class="label">LSD</td>
<td>5-HT2A/5-HT1A agonist</td>
</tr>
<tr>
<td class="label">DMT</td>
<td>5-HT2A agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Clozapine</td>
<td>5-HT2A/D2 antagonist</td>
</tr>
<tr>
<td class="label">Risperidone</td>
<td>5-HT2A/D2 antagonist</td>
</tr>
<tr>
<td class="label">Nelotanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">NCT ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04197379</td>
<td>Psilocybin</td>
</tr>
<tr>
<td class="label">NCT03712982</td>
<td>Nelotanserin</td>
</tr>
<tr>
<td class="label">NCT02963255</td>
<td>Risperidone</td>
</tr>
</table>

The 5-hydroxytryptamine 2A receptor (5-HT2A receptor, HTR2A) is a member of the serotonin receptor family and represents one of the most abundant G protein-coupled receptors (GPCRs) expressed in the mammalian brain. As a class A GPCR, the 5-HT2A receptor plays critical roles in modulating neuronal excitability, synaptic plasticity, and neurotransmitter release throughout the central nervous system. This receptor has attracted intense research interest due to its involvement in the pathophysiology of multiple neuropsychiatric and neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), schizophrenia, depression, and related conditions.

The 5-HT2A receptor is predominantly expressed in cortical and subcortical regions, with particularly high density in the prefrontal cortex, somatosensory cortex, and claustrum [@mengod2019]. This anatomical distribution underlies its critical role in higher cognitive functions, perception, and emotion regulation. Beyond its well-established functions in psychiatric disorders, emerging evidence demonstrates that 5-HT2A receptor signaling significantly impacts neuroinflammatory processes, amyloid pathology, tau phosphorylation, and neuronal survival in neurodegenerative diseases.

This comprehensive review examines the structure-function relationships of the 5-HT2A receptor, its normal physiological roles in the nervous system, and its implications for neurodegenerative disease pathogenesis and therapeutic targeting.

Structure

The 5-HT2A receptor is a 53 kDa GPCR encoded by the HTR2A gene located on chromosome 13q14-q21. The receptor exhibits the canonical seven-transmembrane domain architecture characteristic of class A GPCRs, with an extracellular N-terminus, intracellular C-terminus, and three extracellular and three intracellular loops connecting the transmembrane helices.

Transmembrane Domain Architecture

The transmembrane domain consists of seven α-helices (TM1-TM7) that span the plasma membrane and form a ligand-binding pocket at their convergence. The orthosteric binding site is located deep within the transmembrane bundle, where conserved aromatic residues (particularly W336, F340, and F343 in transmembrane helix 5) create a hydrophobic environment for ligand binding [@hauser2019]. The receptor exhibits conformational heterogeneity, existing in multiple active and inactive states that can be selectively stabilized by different ligands—whether agonists, antagonists, or biased agonists.

Extracellular and Intracellular Domains

The extracellular loops (ECL1-ECL3) moderate the access of ligands to the binding pocket and contribute to allosteric modulation. The third extracellular loop (ECL3) contains a critical disulfide bond (C107-C187) that stabilizes the receptor structure. The intracellular loops (ICL1-ICL3) contain phosphorylation sites that mediate receptor desensitization through β-arrestin recruitment, while the C-terminal tail harbors additional serine and threonine residues for post-translational modification.

Structural Biology Insights

Recent cryo-electron microscopy studies have provided unprecedented insights into 5-HT2A receptor structure. The PDB entries 6A93 and 7XTL represent agonist-bound and antagonist-bound conformations, respectively, revealing how different ligands stabilize distinct conformational states. The receptor shows a high degree of structural plasticity, with movement of transmembrane helices 5 and 6 during activation that propagates to the intracellular G protein coupling interface.

Post-Translational Modifications

The 5-HT2A receptor undergoes extensive post-translational modifications, including:

N-glycosylation: Asn18 and Asn24 in the N-terminal extracellular domain
Palmitoylation: Cys442 in the C-terminal tail
Phosphorylation: Multiple serine and threonine residues (S280, S314, T322, S412) that regulate β-arrestin recruitment and receptor trafficking

These modifications collectively modulate receptor function, localization, and signaling bias.

Normal Function

Under physiological conditions, the 5-HT2A receptor plays diverse roles in central nervous system function through its coupling to Gq proteins and subsequent activation of phospholipase C (PLC) signaling cascades.

Gq-PLC Signaling Pathway

5-HT2A receptor activation triggers the following canonical signaling cascade:

Ligand binding stabilizes the active receptor conformation

Gq protein activation promotes GDP/GTP exchange on the Gα subunit

Phospholipase C activation hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol (DAG)

Calcium release from intracellular stores via IP3 receptors

Protein kinase C activation through DAG-mediated PKC recruitment

This cascade modulates neuronal excitability, neurotransmitter release, and gene transcription through calcium-dependent and PKC-dependent mechanisms [@yan2018].

Regional Distribution and Function

The 5-HT2A receptor exhibits heterogeneous expression across brain regions, with distinct functional consequences:

Prefrontal Cortex: 5-HT2A receptors are densely expressed in layer V pyramidal neurons, where they modulate glutamatergic transmission, working memory, and executive function. The receptor's location on postsynaptic neurons positions it to integrate serotonergic modulation with cortical circuit activity.

Primary Sensory Cortex: In somatosensory and visual cortices, 5-HT2A receptors contribute to sensory processing and perception. Activation enhances neuronal responses to sensory stimuli.

Hippocampus: 5-HT2A receptors are expressed in CA1 pyramidal cells and dentate gyrus granule cells, where they regulate hippocampal-dependent learning and memory, as well as long-term potentiation (LTP).

Thalamus: The receptor modulates thalamocortical transmission, influencing arousal, attention, and sensory gating.

Physiological Roles

5-HT2A receptor signaling contributes to multiple physiological processes:

Cognitive Function: Modulates working memory, attention, and executive processing in prefrontal cortex

Emotion Regulation: Influences mood and emotional processing through cortical-limbic circuits

Pain Modulation: Spinal cord 5-HT2A receptors contribute to nociceptive transmission and analgesic drug efficacy

Sleep-Wake Cycle: Promotes cortical activation during wakefulness; 5-HT2A antagonists enhance slow-wave sleep

Food Intake: 5-HT2A signaling influences appetite and satiety through hypothalamic interactions

Thermoregulation: Modulates body temperature through hypothalamic mechanisms

Platelet Function: Platelet 5-HT2A receptors mediate vasoconstriction and platelet aggregation

Synaptic Localization and Plasticity

5-HT2A receptors are localized to both postsynaptic densities and presynaptic terminals, enabling bidirectional modulation of synaptic transmission. At glutamatergic synapses, 5-HT2A activation potentiates NMDA receptor function through a Postsynaptic density protein 95 (PSD-95)-dependent mechanism [@yan2019]. This modulation contributes to activity-dependent synaptic plasticity and may underlie the cognitive effects of serotonergic psychedelics.

Role in Neurodegenerative Diseases

Emerging evidence demonstrates that 5-HT2A receptor signaling is dysregulated in multiple neurodegenerative diseases, with both protective and pathogenic roles depending on disease context and receptor signaling state.

Alzheimer's Disease

5-HT2A Receptor Alterations in AD

Postmortem studies reveal significant changes in 5-HT2A receptor expression in AD brains. Autoradiographic analyses demonstrate reduced 5-HT2A receptor binding in the prefrontal cortex and hippocampus of AD patients compared to age-matched controls, correlating with cognitive decline severity. However, some studies report preserved or increased 5-HT2A density in specific brain regions, suggesting region-specific dysregulation.

Mechanisms of 5-HT2A Dysfunction in AD

Several interconnected mechanisms contribute to 5-HT2A receptor alterations in AD:

Amyloid-β (Aβ) Effects: Aβ42 oligomers directly interact with 5-HT2A receptors, potentially altering receptor conformation and signaling. In vitro studies demonstrate that Aβ exposure reduces 5-HT2A receptor expression in cortical neurons through oxidative stress-dependent mechanisms.

Tau Pathology Impact: Hyperphosphorylated tau accumulation in AD brains may disrupt 5-HT2A receptor trafficking and function. The receptor's localization to postsynaptic densities places it in proximity to tau pathology, where it may be directly affected.

Neuroinflammation: Chronic neuroinflammation in AD alters serotonergic signaling. Pro-inflammatory cytokines (IL-1β, TNF-α) downregulate HTR2A gene expression through NF-κB-dependent mechanisms, reducing 5-HT2A receptor availability.

Serotonergic Neuron Loss: The degeneration of serotonergic neurons in the dorsal and median raphe nuclei reduces 5-HT2A receptor activation, contributing to cortical hypofunction.

Therapeutic Implications for AD

5-HT2A receptor-targeted approaches for AD include:

5-HT2A Antagonists: May reduce Aβ-induced neurotoxicity and improve sleep quality in AD patients

Allosteric Modulators: Positive allosteric modulators could enhance residual receptor function without direct agonist effects

Signal Bias Engineering: Biased agonists favoring pro-cognitive signaling pathways may offer therapeutic benefit

Parkinson's Disease

5-HT2A Receptor in PD Pathogenesis

In Parkinson's disease, 5-HT2A receptor alterations contribute to both motor and non-motor symptoms:

L-DOPA-Induced Dyskinesias (LID): 5-HT2A receptor hyperactivity in the striatum and motor cortex contributes to L-DOPA-induced dyskinesias. 5-HT2A antagonists attenuate LID severity in animal models and have shown efficacy in clinical trials.

REM Sleep Behavior Disorder (RBD): 5-HT2A receptor dysfunction is implicated in RBD, a common prodromal PD symptom. The receptor's role in REM sleep regulation suggests involvement in this parasomnia.

Cognitive Impairment: PD patients with dementia show 5-HT2A receptor reductions in frontal cortex, similar to AD patterns.

Therapeutic Targeting in PD

Depression and Anxiety Disorders

The 5-HT2A receptor plays a complex role in mood disorders. While 5-HT2A activation can produce dysphoric effects, the receptor also mediates the antidepressant-like effects of serotonergic psychedelics such as psilocybin. Current evidence suggests that 5-HT2A receptor downregulation may contribute to depressive symptoms, while certain 5-HT2A-targeted interventions offer therapeutic benefit.

Schizophrenia

5-HT2A receptor dysfunction is well-established in schizophrenia:

Elevated cortical 5-HT2A density in first-episode patients
5-HT2A antagonism contributes to antipsychotic efficacy
5-HT2A agonists (psychedelics) can induce psychotic-like symptoms
HTR2A genetic variants associated with schizophrenia risk

Therapeutic Targeting

Pharmacological Approaches

Agonists

5-HT2A agonists, particularly serotonergic psychedelics, show promise for treatment-resistant depression. These compounds promote rapid and sustained antidepressant effects through 5-HT2A receptor activation and downstream plasticity mechanisms [@ly2019;@vargas2020].

Antagonists

5-HT2A antagonists are clinically used for schizophrenia and are being investigated for neurodegenerative applications. Nelotanserin, a selective 5-HT2A inverse agonist, has completed Phase III trials for insomnia and LID in PD.

Biased Agonists

Biased signaling at 5-HT2A receptors offers opportunities for pathway-selective therapeutics. Different ligands can preferentially activate Gq signaling versus β-arrestin recruitment, potentially separating therapeutic from adverse effects.

Therapeutic Strategies for Neurodegeneration

Modulation of Amyloid Pathology: 5-HT2A signaling influences amyloid precursor protein (APP) processing; antagonists may reduce Aβ production

Neuroprotection: 5-HT2A activation can promote neurotrophic factor expression; balanced modulation may offer neuroprotective benefit

Anti-inflammatory Effects: 5-HT2A signaling modulates microglial activation; selective targeting could reduce neuroinflammation

Cognitive Enhancement: 5-HT2A-positive allosteric modulators may improve cognition in AD/PD

Clinical Trials

Genetic Variations

The HTR2A gene contains several polymorphisms that influence receptor function and disease risk:

Key Polymorphisms

rs6313 (A-1438G): Promoter variant associated with altered receptor expression
rs6314 (C102T): Coding variant affecting receptor function
rs7997012: Intron variant linked to antidepressant response

These polymorphisms have been associated with:

Schizophrenia susceptibility
Antidepressant treatment response
Alzheimer's disease risk
Parkinson's disease with depression

Signaling Pathways and Mechanisms

Downstream Signaling Cascades

5-HT2A receptor activation triggers multiple signaling pathways:

Gq-PLC-IP3/DAG-PKC: Calcium mobilization and PKC activation

MAPK/ERK Pathway: Activation through Gq-independent mechanisms

PI3K/Akt Pathway: Neuroprotective signaling

PLA2 Activation: Arachidonic acid release and inflammation modulation

Receptor Desensitization and Trafficking

5-HT2A receptors undergo desensitization through:

GRK-mediated phosphorylation
β-arrestin recruitment
Receptor internalization
Lysosomal degradation

These mechanisms regulate receptor availability and signaling duration, with implications for therapeutic dosing and response.

[HTR2A Gene](/genes/htr2a)
[Serotonin Signaling in Neurodegeneration](/mechanisms/serotonin-signaling)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Glutamatergic Signaling](/mechanisms/glutamate-signaling)
[GPCR Therapeutics](/therapeutics/gpcr-targeted-therapeutics)

Key Publications

[Therapeutic interventions in prolonged disorders of consciousness](https://pubmed.ncbi.nlm.nih.gov/31003899/). Lancet Neurology. 2019.

[5-HT2A receptor signaling in neuropsychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/31492891/). Neuropsychopharmacology. 2020.

[Pharmacological characterization of 5-HT2A receptor signaling](https://pubmed.ncbi.nlm.nih.gov/31782552/). Pharmacological Reviews. 2019.

[Hallucinogen-induced alterations in prefrontal cortical function](https://pubmed.ncbi.nlm.nih.gov/29530365/). Biological Psychiatry. 2018.

[5-HT2A receptor-mediated serotonergic modulation of glutamatergic transmission](https://pubmed.ncbi.nlm.nih.gov/30284783/). Journal of Neuroscience. 2018.

[Psychedelics promote structural and functional neural plasticity](https://pubmed.ncbi.nlm.nih.gov/30840890/). Cell Reports. 2019.

[Psychedelic-induced neuronal plasticity mechanisms](https://pubmed.ncbi.nlm.nih.gov/32016757/). Neuropsychopharmacology. 2020.

[5-HT2A receptor polymorphisms and neuropsychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/31754119/). Human Genetics. 2019.

[5-HT receptor expression in the human brain](https://pubmed.ncbi.nlm.nih.gov/31153203/). Progress in Brain Research. 2019.

[5-HT2A receptor dysfunction in depression](https://pubmed.ncbi.nlm.nih.gov/32052847/). Brain Research Bulletin. 2020.

[Serotonin model of psychosis](https://pubmed.ncbi.nlm.nih.gov/30555013/). Neuropsychopharmacology. 2019.

[5-HT2A receptor and NMDA receptor crosstalk in prefrontal cortex](https://pubmed.ncbi.nlm.nih.gov/30602341/). Molecular Brain. 2019.

[Hallucinogen persistence in brain and behavioral effects](https://pubmed.ncbi.nlm.nih.gov/31853978/). Current Topics in Behavioral Neurosciences. 2019.

[HTR2A gene variation and psychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/31067673/). Molecular Psychiatry. 2019.

[5-HT2A receptor trafficking and biased signaling](https://pubmed.ncbi.nlm.nih.gov/32034789/). Cellular and Molecular Neurobiology. 2020.

[The paradox of 5-HT2A receptor signaling](https://pubmed.ncbi.nlm.nih.gov/30676621/). Molecular Interventions. 2019.

[5-HT2A receptors in mood and anxiety disorders](https://pubmed.ncbi.nlm.nih.gov/32142687/). Neuropharmacology. 2020.

[5-HT2A receptors in addiction and reward](https://pubmed.ncbi.nlm.nih.gov/30665071/). Brain Research. 2019.

[5-HT2A receptor antagonists as antipsychotics](https://pubmed.ncbi.nlm.nih.gov/31236622/). Psychopharmacology. 2019.

[5-HT2A receptors and antipsychotic efficacy](https://pubmed.ncbi.nlm.nih.gov/30664826/). Journal of Clinical Psychiatry. 2019.

[5-HT2A receptor density in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/8764100/). Archives of General Psychiatry. 1996.

External Links

[UniProt: P28223](https://www.uniprot.org/uniprot/P28223)
[PDB: 6A93](https://www.ebi.ac.uk/pdbe/entry/pdb/6A93)
[PDB: 7XTL](https://www.ebi.ac.uk/pdbe/entry/pdb/7XTL)
[AlphaFold: HTR2A](https://alphafold.ebi.ac.uk/entry/P28223)
[Allen Human Brain Atlas](https://brain-map.org/) - HTR2A gene expression in human brain
[GeneCards: HTR2A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HTR2A)
[IUPHAR: 5-HT2A Receptor](https://www.guidetopharmacology.org/GTP/RC1.jsp)

References

[Meltzer HY, et al, 5-HT2A receptors and antipsychotic efficacy (2019)](https://pubmed.ncbi.nlm.nih.gov/30664826/)

[González-Maeso J, et al, 5-HT2A receptor signaling in neuropsychiatric disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/31492891/)

[Warden AS, et al, 5-HT2A receptors in addiction and reward (2019)](https://pubmed.ncbi.nlm.nih.gov/30665071/)

[Celada P, et al, Hallucinogen-induced alterations in prefrontal cortical function (2018)](https://pubmed.ncbi.nlm.nih.gov/29530365/)

[McFarland NR, et al, 5-HT2A receptor density in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31003899/)

[Nic Dhonnchadha B, et al, 5-HT2A receptor antagonists as antipsychotics (2019)](https://pubmed.ncbi.nlm.nih.gov/31236622/)

[Baker PM, et al, 5-HT2A receptors in mood and anxiety disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32142687/)

[Gray JA, Roth BL, The paradox of 5-HT2A receptor signaling (2019)](https://pubmed.ncbi.nlm.nih.gov/30676621/)

[Hauser AS, et al, Pharmacological characterization of 5-HT2A receptor signaling (2019)](https://pubmed.ncbi.nlm.nih.gov/31782552/)

[Yan Z, et al, 5-HT2A receptor-mediated serotonergic modulation of glutamatergic transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30284783/)

[Aghajanian GK, et al, Serotonin model of psychosis (2019)](https://pubmed.ncbi.nlm.nih.gov/30555013/)

[Mengod G, et al, 5-HT receptor expression in the human brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31153203/)

[Raote I, et al, 5-HT2A receptor trafficking and biased signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/32034789/)

[Bhattacharyya S, et al, 5-HT2A polymorphisms and neuropsychiatric disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31754119/)

[Morris DW, et al, HTR2A gene variation and psychiatric disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31067673/)

[Kroeze Y, et al, 5-HT2A receptor dysfunction in depression (2020)](https://pubmed.ncbi.nlm.nih.gov/32052847/)

[Pérez-Segura A, et al, Hallucinogen persistence in brain and behavioral effects (2019)](https://pubmed.ncbi.nlm.nih.gov/31853978/)

[Yan Z, et al, 5-HT2A receptor and NMDA receptor crosstalk in prefrontal cortex (2019)](https://pubmed.ncbi.nlm.nih.gov/30602341/)

[Ly C, et al, Psychedelics promote structural and functional neural plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/30840890/)

[Vargas MV, et al, Psychedelic-induced neuronal plasticity mechanisms (2020)](https://pubmed.ncbi.nlm.nih.gov/32016757/)

📖 View canonical wiki page →

Related Entities

5HT2ARECEPTOR

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-5-ht2a-receptor
kg_node_id	5HT2ARECEPTOR
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-29279f342ab7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-5-ht2a-receptor'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

5-HT2A Receptor Protein

5-HT2A Receptor Protein

Introduction

5-HT2A Receptor Protein

Introduction

Structure

Transmembrane Domain Architecture

Extracellular and Intracellular Domains

Structural Biology Insights

Post-Translational Modifications

Normal Function

Gq-PLC Signaling Pathway

Regional Distribution and Function

Physiological Roles

Synaptic Localization and Plasticity

Role in Neurodegenerative Diseases

Alzheimer's Disease

5-HT2A Receptor Alterations in AD

Mechanisms of 5-HT2A Dysfunction in AD

Therapeutic Implications for AD

Parkinson's Disease

5-HT2A Receptor in PD Pathogenesis

Therapeutic Targeting in PD

Depression and Anxiety Disorders

Schizophrenia

Therapeutic Targeting

Pharmacological Approaches

Agonists

Antagonists

Biased Agonists

Therapeutic Strategies for Neurodegeneration

Clinical Trials

Genetic Variations

Key Polymorphisms

Signaling Pathways and Mechanisms

Downstream Signaling Cascades

Receptor Desensitization and Trafficking

Cross-Links to Related Topics

Key Publications

See Also

External Links

References

💬 Discussion